Intel Corporation

Nanosys, Inc.

Applied Materials, Inc.

Nippon Telegraph and Telephone Corporation

Bristol-myers Squibb Compnay

Other

Sharp Kabushiki Kaisha Corporation

Provention Bio, Inc.

Amgen Inc.

Yale University

Oned Material, Inc.

Applied Material, Inc.

Celimmune LLC

Benaroya Research Institure at Virginia Mason

Francisco A Leon

Satoshi Tazawa

David P Stumbo

Lawrence Camest West

J Wallace Parce

Jian Chen

Yaoling Pan

Linda T Romano

Xiangfeng Duan

Yuichi Wada

Jeffrey L Miller

Gregory L Wojcik

Shahriar Mostarshed

Cheri X Y Pereira

Akira Yoshii

Kazuyuki Saito

Hiroshi Iwata

Akihide Shibata

Stephen Moffatt

Paul John Schuele

Hiroshi Ohki

Vivek K Singh

Gregory Wayne Anderson

James M Hamilton

Katsumasa Fujii

Everett X Wang

Tetsu Negishi

Samuel Edward Martin

Robert Martin Townsend

Yasunobu Okada

John Ernst Bjorkholm

Kevan C Herold

Donald L Scharfetter

Catherine Aversa Fleener

Brian S Doyle

Robert S Dubrow

Peter S Linsley

Chunming Niu

Richard E Schenker

William P Freeman

Stephen A Empedocles

Andreas Goebel

Jay L Goldman

Francesco Lemmi

Veeral Hardev

David Dutton

Yonah Cho

Thomas P Pearsall

Lee K Tay

Wayne H Tsuji

George Vratsanos

Jay S Skyler

Carlos Casillas

Kenneth M Bahrt

Tetsuya Abe

Donald L Sharfetter

Sarah Alice Long

Catherine A Fleener

Provided herein, in one aspect, is a method of preventing or delaying the onset of clinical type 1 diabetes (T1D), comprising: providing a non-diabetic subject who is at risk for T1D; administering a prophylactically effective amount of an anti-CD3 antibody to the non-diabetic subject; and determining, prior to or after the administering step, that the non-diabetic subject has more than about 5% to more than about 10% TIGIT+KLRG1+CD8+ T-cells in all CD3+ T cells, which is indicative of successful prevention or delay of the onset of clinical T1D.

Methods and compositions for preventing type 1 diabetes

Methods and pharmaceutical compositions are provided herein for the treatment of inflammatory disorders, in particular celiac disease, refractory celiac disease and non-celiac gluten sensitivity.

Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease

Provided herein, in one aspect, is a method of preventing or delaying the onset of clinical type 1 diabetes (T1D), comprising: providing a non-diabetic subject who is at risk for T1D; determining that the non-diabetic subject (1) is substantially free of antibodies against zinc transporter 8 (ZnT8), (2) is HLA-DR4+, and/or (3) is not HLA-DR3+; and administering a prophylactically effective amount of an anti-CD3 antibody to the non-diabetic subject.

The present invention relates to methods of forming substrate elements, including semiconductor elements such as nanowires, transistors and other structures, as well as the elements formed by such methods.

Methods for formation of substrate elements

The present invention discloses a method for assaying the binding of L104EA29YIg to a receptor. The receptor is preferably CD86 or CD80. The present invention also discloses antibodies to be used in the assay, as well as hybridomas expressing the antibodies.

Anti-CD80 antibody

Anti-CD86 antibody

The present invention provides methods and systems for nanowire alignment and deposition. Energizing (e.g., an alternating current electric field) is used to align and associate nanowires with electrodes. By modulating the energizing, the nanowires are coupled to the electrodes such that they remain in place during subsequent wash and drying steps. The invention also provides methods for transferring nanowires from one substrate to another in order to prepare various device substrates. The present invention also provides methods for monitoring and controlling the number of nanowires deposited at a particular electrode pair, as well as methods for manipulating nanowires in solution.

Methods for nanowire alignment and deposition

A nonvolatile memory cell includes a substrate comprising a source, drain, and channel between the source and the drain. A tunnel dielectric layer overlies the channel, and a localized charge storage layer is disposed between the tunnel dielectric layer and a control dielectric layer. A gate electrode has a first surface adjacent to the control dielectric layer, and the first surface includes a midsection and two edge portions. According to one embodiment, the midsection defines a plane, and at least one edge portion extends away from the plane. Preferably, the edge portion extending away from the plane converges toward an opposing second surface of the gate electrode. According to another embodiment, the gate electrode of the nonvolatile memory cell includes a first sublayer and a second sublayer of a different width on the first sublayer.

Gate electrode for a nonvolatile memory cell

Methods, systems, and apparatuses for electronic devices having improved gate structures are described. An electronic device includes at least one nanowire. A gate contact is positioned along at least a portion of a length of the at least one nanowire. A dielectric material layer is between the gate contact and the at least one nanowire. A source contact and a drain contact are in contact with the at least one nanowire. At least a portion of the source contact and/or the drain contact overlaps with the gate contact along the nanowire the length. In another aspect, an electronic device includes a nanowire having a semiconductor core surrounded by an insulating shell layer. A ring shaped first gate region surrounds the nanowire along a portion of the length of the nanowire. A second gate region is positioned along the length of the nanowire between the nanowire and the substrate. A source contact and a drain contact are coupled to the semiconductor core of the nanowire at respective exposed portions of the semiconductor core.

Method of fabricating gate configurations for an improved contacts in nanowire based electronic devices

A method of fabricating on a substrate an optical detector in an optical waveguide, the method involving: forming at least one layer on a surface of the substrate, said at least one layer comprising SiGe; implanting an impurity into the at least one layer over a first area to form a detector region for the optical detector; etching into the at least one layer in a first region and a second region to form a ridge between the first and second regions, said ridge defining the optical detector and the optical waveguide; filling the first and second regions with a dielectric material having a lower refractive index than SiGe; and after filling the first and second regions with the dielectric material, removing surface material to form a planarized upper surface.

Ridge technique for fabricating an optical detector and an optical waveguide

Gating configurations and improved contacts in nanowire-based electronic devices

Porous and/or curved nanofiber bearing substrate materials are provided having enhanced surface area for a variety of applications including as electrical substrates, semipermeable membranes and barriers, structural lattices for tissue culturing and for composite materials, production of long unbranched nanofibers, and the like.

Porous substrates, articles, systems and compositions comprising nanofibers and methods of their use and production

The present invention relates to methods of vaccinating subjects receiving immune modulating therapy, such as soluble CTLA4 molecules, for treatment of immune system diseases mediated by T-cell interactions with B7-positive cells including, but not limited to, autoimmune diseases, immunoproliferative diseases, and immune disorders associated with graft transplantation.

Method of vaccinating subjects receiving immune modulating therapy

CD86 and CD80 receptor competition assays

Growing community of inventors

Mountain View, CA, United States of America

Francisco A Leon